We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeut... Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. Show more
0001159036PRE 14Afalse00011590362023-01-012023-12-31iso4217:USD00011590362022-01-012022-12-3100011590362021-01-012021-12-3100011590362020-01-012020-12-310001159036ecd:PeoMemberhalo:EquityAwardsOpti...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
="/Images/box-unchecked.jpg" alt="Checkbox not checked">252902/16/2024Not Applicable* If the securities were purchased and full payment therefor was not made in cash at the time of purchase...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
="/Images/box-unchecked.jpg" alt="Checkbox not checked">217802/15/2024Not Applicable* If the securities were purchased and full payment therefor was not made in cash at the time of purchase...
Halozyme to Participate in Upcoming Investor Conferences PR Newswire SAN DIEGO, Feb. 27, 2024 SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.17 | 0.41779306955 | 40.69 | 42.3 | 39.9 | 724642 | 40.28686827 | CS |
4 | 0.62 | 1.5407554672 | 40.24 | 42.64 | 39.39 | 983068 | 40.90079342 | CS |
12 | 4.98 | 13.8795986622 | 35.88 | 42.64 | 33.15 | 1349823 | 37.01915496 | CS |
26 | 2.45 | 6.37854725332 | 38.41 | 42.82 | 32.83 | 1143127 | 37.32783366 | CS |
52 | 5.32 | 14.9690489589 | 35.54 | 45 | 29.85 | 1131482 | 37.27786877 | CS |
156 | -0.14 | -0.341463414634 | 41 | 59.46 | 29.85 | 1105315 | 41.25035965 | CS |
260 | 25.24 | 161.587708067 | 15.62 | 59.46 | 12.71 | 1196280 | 34.53883413 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions